Amantadine Treatment for People with COVID-19

SARS-Cov-2, whose symptoms include difficulty swallowing, coughing, diarrhea, and breathing failure, has caused the loss of many lives around the world. In the absence of a vaccine or medication to help prevent or decrease the effects of the disease, we suggest that amantadine may reduce the effects...

Descripción completa

Detalles Bibliográficos
Autores principales: Araújo, Ramiro, Aranda-Martínez, José Dolores, Aranda-Abreu, Gonzalo Emiliano
Formato: Online Artículo Texto
Lenguaje:English
Publicado: IMSS. Published by Elsevier Inc. 2020
Materias:
Opinion
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7290190/
https://www.ncbi.nlm.nih.gov/pubmed/32571606
http://dx.doi.org/10.1016/j.arcmed.2020.06.009
_version_ 1783545618513264640
author Araújo, Ramiro
Aranda-Martínez, José Dolores
Aranda-Abreu, Gonzalo Emiliano
author_facet Araújo, Ramiro
Aranda-Martínez, José Dolores
Aranda-Abreu, Gonzalo Emiliano
author_sort Araújo, Ramiro
collection PubMed
description SARS-Cov-2, whose symptoms include difficulty swallowing, coughing, diarrhea, and breathing failure, has caused the loss of many lives around the world. In the absence of a vaccine or medication to help prevent or decrease the effects of the disease, we suggest that amantadine may reduce the effects of COVID-19.
format Online
Article
Text
id pubmed-7290190
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher IMSS. Published by Elsevier Inc.
record_format MEDLINE/PubMed
spelling pubmed-72901902020-06-12 Amantadine Treatment for People with COVID-19 Araújo, Ramiro Aranda-Martínez, José Dolores Aranda-Abreu, Gonzalo Emiliano Arch Med Res Opinion SARS-Cov-2, whose symptoms include difficulty swallowing, coughing, diarrhea, and breathing failure, has caused the loss of many lives around the world. In the absence of a vaccine or medication to help prevent or decrease the effects of the disease, we suggest that amantadine may reduce the effects of COVID-19. IMSS. Published by Elsevier Inc. 2020-10 2020-06-12 /pmc/articles/PMC7290190/ /pubmed/32571606 http://dx.doi.org/10.1016/j.arcmed.2020.06.009 Text en © 2020 IMSS. Published by Elsevier Inc. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Opinion
Araújo, Ramiro
Aranda-Martínez, José Dolores
Aranda-Abreu, Gonzalo Emiliano
Amantadine Treatment for People with COVID-19
title Amantadine Treatment for People with COVID-19
title_full Amantadine Treatment for People with COVID-19
title_fullStr Amantadine Treatment for People with COVID-19
title_full_unstemmed Amantadine Treatment for People with COVID-19
title_short Amantadine Treatment for People with COVID-19
title_sort amantadine treatment for people with covid-19
topic Opinion
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7290190/
https://www.ncbi.nlm.nih.gov/pubmed/32571606
http://dx.doi.org/10.1016/j.arcmed.2020.06.009
work_keys_str_mv AT araujoramiro amantadinetreatmentforpeoplewithcovid19
AT arandamartinezjosedolores amantadinetreatmentforpeoplewithcovid19
AT arandaabreugonzaloemiliano amantadinetreatmentforpeoplewithcovid19

Ejemplares similares